Endospan brings together a seasoned team of researchers, engineers and executives in the MedTech field. Backed by leading global venture groups, Endospan is focused on becoming a dominant competitor in the endovascular aortic repair market.
The Endospan platform is innovative, opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The novel design of Endospan’s systems presents a true advancement when compared to traditional EVAR/TEVAR systems, enhancing endografts with gold-standard material durability, intra-procedural stability, and a shorter, simpler and less-invasive procedure.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX, formerly Biotech and Money, is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.